This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Changes in cognitive functions of patients with dementia of the Alzheimer type following long-term administration of donepezil hydrochloride: Relating to changes attributable to differences in apolipoprotein E phenotype

Authors

Kanaya, Kiyoshi, Abe, Shine, Sakai, Minoru, Fujii, Hiroko, Iwamoto, Toshihiko

Journal

Geriatrics & Gerontology International, Volume: 10, No.: 1, Pages.: 25-31

Year of Publication

2010

Abstract

Aim: We conducted a study of changes in cognitive functions by long-term monitoring of dementia of Alzheimer type (DAT) patients to investigate the relationship between the progression of DAT symptoms and the presence of apolipoprotein (ApoE)4. Methods: The subjects consisted of 40 DAT patients who had been treated with donepezil for 3 years or more. The Mini-Mental State Examination (MMSE) and Alzheimer’s Disease Assessment Scale – Cognitive Subscale Japanese version (ADAS-Jcog), were conducted annually. The patients were categorized into ApoE4+ and ApoE4- groups. Changes in initial cognitive function assessment score (0 years) were then studied longitudinally at each stage of the observation period (1, 2, 3 years) (Wilcoxon’s signed-rank test). Moreover, the scores at each time period were compared cross-sectionally between the two groups (Mann-Whitney U-test). Results: Significant decreases in MMSE scores were observed at the three time periods in both groups (P < 0.01) in the cross-sectional study. In the longitudinal study, the ApoE4+ group demonstrated a lower trend (P < 0.1) after 1 year only. Significantly poorer ADAS-Jcog scores were observed in the ApoE4+ group at the 3-year point both in the longitudinal and in the cross-sectional study (P < 0.05). For ADAS-Jcog sub-items, in the longitudinal study, orientation was demonstrated to be significantly poorer in the ApoE4+ group in the third year (P < 0.05). Conclusion: ApoE4 was suggested to not only be a risk factor for disease onset, but also a risk factor for exacerbation of symptoms with respect to long-term prognosis. (PsycINFO Database Record (c) 2012 APA, all rights reserved). (journal abstract)

Bibtex Citation

@article{Kanaya_2010, doi = {10.1111/j.1447-0594.2009.00551.x}, url = {http://dx.doi.org/10.1111/j.1447-0594.2009.00551.x}, year = 2010, month = {jan}, publisher = {Wiley-Blackwell}, volume = {10}, number = {1}, pages = {25--31}, author = {Kiyoshi Kanaya and Shine Abe and Minoru Sakai and Hiroko Fujii and Toshihiko Iwamoto}, title = {Changes in cognitive functions of patients with dementia of the Alzheimer type following long-term administration of donepezil hydrochloride: Relating to changes attributable to differences in apolipoprotein E phenotype}, journal = {Geriatrics {&} Gerontology International} }

Keywords

alzheimer’s disease, apolipoproteins, cognitive ability, cognitive functions, dementia, donepezil, donepezil hydrochloride, psychiatric symptoms, symptoms

Countries of Study

Japan

Types of Dementia

Alzheimer’s Disease

Types of Study

Cohort Study

Type of Outcomes

Cognition

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime